Prostate cancer Book Section


Authors: Grossman, C. E.; Gorovets, D.; Zelefsky, M. J.
Editors: Cuaron, J. J.; Braunstein, L. Z.
Article/Chapter Title: Prostate cancer
Abstract: Prostate cancer is the most common cancer and the second leading cause of cancer death among men in the United States. Definitive treatment with either surgery or radiation (with or without androgen deprivation therapy, ADT) is currently guided by the National Comprehensive Cancer Network’s (NCCN) risk stratification prognostic groupings, which are based on clinical tumor stage, biopsy Gleason score (GS) and percentage of positive cores, and pretreatment serum PSA. To better prognosticate patients at diagnosis, tissue-based molecular biomarkers (i.e., Decipher and Oncotype DX Genomic Prostate Scores, and ArteraAI multimodal artificial intelligence biomarker test) and improved imaging techniques (i.e., Prostate-Specific Membrane Antigen (PSMA) radiotracer and enhanced MR capabilities) will likely be incorporated into management decisions over time. Treatment practices will continue to advance with the goals of decreasing treatment duration, reducing toxicity, and further improving cure rates. The patient’s decision to pursue a radiotherapy versus surgical approach, knowing that oncologic outcomes are equivalent, is multifactorial and based on social, psychological, financial, comorbid, toxicity, and other considerations. © The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2025.
Keywords: chemotherapy; radiotherapy; biopsy; active surveillance; urology; androgen deprivation therapy; arthroplasty; prostate cancers; prostate brachytherapy; robotic surgery; transplantation (surgical); high-risk prostate cancer; transplants; intermediate risks; androgen deprivation therapy (adt); salvage radiation; low-risk prostate cancer; prostate sbrt; medicaments; favorable intermediate-risk prostate cancer; unfavorable intermediate-risk prostate cancer; high-risk prostate cancers
Book Title: Radiation Oncology Clinical Fundamentals
ISBN: 978-3-031-77558-1
Publisher: Springer Nature  
Publication Place: Cham, Switzerland
Date Published: 2025-01-01
Start Page: 83
End Page: 95
Language: English
DOI: 10.1007/978-3-031-77559-8_7
PROVIDER: scopus
DOI/URL:
Notes: Book chapter: 7 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Michael J Zelefsky
    754 Zelefsky
  2. John Jacob Cuaron
    142 Cuaron